Eli Lilly &Amp; Co (LLY) — 8-K Filings

8-K Filings (16)

• Eli Lilly Files 8-K with Q1 2026 Financials — Apr 30, 2026 Risk: low
  On April 30, 2026, Eli Lilly and Company filed an 8-K report detailing their financial results for the period ending April 30, 2026. The filing includes informa
• 8-K Filing — Nov 21, 2025
• Eli Lilly Files 8-K on Debt Instruments — Aug 20, 2025 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on August 20, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of August 18, 2025. The filing
• Eli Lilly Files 8-K on Security Holder Votes and Debt — May 8, 2025 Risk: low
  Eli Lilly & Co. filed an 8-K on May 8, 2025, to report the submission of matters to a vote of security holders. The filing details various debt instruments, inc
• Eli Lilly Files 8-K Detailing Debt Offerings — Feb 12, 2025 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing details various debt issuances, inclu
• Eli Lilly Files 8-K on Financials and Debt — Feb 6, 2025 Risk: low
  Eli Lilly and Company filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Eli Lilly Files 8-K on Financials — Jan 14, 2025 Risk: low
  Eli Lilly and Company filed an 8-K on January 14, 2025, to report on its results of operations and financial condition. The filing includes various financial st
• Eli Lilly Elects New Directors, Adjusts Officer Compensation — Nov 19, 2024 Risk: low
  On November 19, 2024, Eli Lilly and Company (LLY) filed an 8-K detailing the election of new directors and changes in executive compensation. Specifically, the
• Eli Lilly Files 8-K: Director Changes and Compensation Details — Sep 9, 2024 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on September 9, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, includ
• Eli Lilly Files 8-K: Director Changes and Officer Compensation — Aug 16, 2024 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on August 16, 2024, reporting on the departure of director Michael J. Smith and the election of new directors, includin
• Eli Lilly Files 8-K on Debt Issuances — Aug 14, 2024 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on August 14, 2024, reporting on other events and financial statements. The filing details various debt issuances, incl
• Eli Lilly Announces Executive Compensation Changes — Jul 10, 2024 Risk: medium
  Eli Lilly & Co. announced on July 5, 2024, changes in its executive compensation arrangements. The filing details the election of new officers and adjustments t
• Eli Lilly Announces Board Changes and Officer Compensation Details — Jun 5, 2024 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on June 5, 2024, reporting on the departure of director Michael L. Smith and the election of new directors, including A
• Eli Lilly Files 8-K on Shareholder Vote Matters — May 9, 2024 Risk: low
  Eli Lilly and Company (LLY) filed an 8-K on May 9, 2024, to report the submission of matters to a vote of security holders. This filing indicates that the compa
• Eli Lilly Updates Debt Instruments in 8-K Filing — Feb 9, 2024 Risk: low
  Eli Lilly and Company filed an 8-K on February 9, 2024, reporting an "Other Event" that occurred on February 7, 2024. This filing primarily updates the company'
• Eli Lilly Files 8-K on Financial Results & Debt Notes — Feb 6, 2024
  Eli Lilly and Company filed an 8-K on February 6, 2024, to report its financial results and condition, specifically mentioning various debt notes with maturity

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX